Low-dose aspirin therapy to prevent preeclampsia
Objective: Our aim was to test the hypothesis that acetylsalicylate (aspirin) treatment reduces the incidence or severity of pregnancy-associated hypertension. Study Design: Patients were nulliparous, healthy, and with a singleton gestation at between 20 and 22 weeks' gestation. A sample size o...
Gespeichert in:
| Veröffentlicht in: | American journal of obstetrics and gynecology 1993-04, Vol.168 (4), p.1083-1093 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1093 |
|---|---|
| container_issue | 4 |
| container_start_page | 1083 |
| container_title | American journal of obstetrics and gynecology |
| container_volume | 168 |
| creator | Hauth, John C. Goldenberg, Robert L. Parker, C. Richard Philips, Joseph B. Copper, Rachel L. DuBard, Mary B. Cutter, Gary R. |
| description | Objective: Our aim was to test the hypothesis that acetylsalicylate (aspirin) treatment reduces the incidence or severity of pregnancy-associated hypertension.
Study Design: Patients were nulliparous, healthy, and with a singleton gestation at between 20 and 22 weeks' gestation. A sample size of 600 patients was calculated on the basis of p ≤ 0.05 and 90% power of observation. A 2-week placebo-controlled “run-in” was used to select compliant patients. Randomization occurred at 24 weeks, with 60 mg of aspirin or placebo treatment from randomization to delivery.
Results: Follow-up was maintained on 99% of the patients. The randomized patients had a 94% pill compliance index. At randomization, serum thromboxane medians were similar in both groups. Thromboxane B2 levels in the aspirin group decreased significantly from baseline at 29 to 31 weeks, 34 to 36 weeks, and at delivery as compared with an overall increase in the placebo group. Preeclampsia developed in five of 302 women (1.7%) who received aspirin versus 17 of 302 (5.6%) who received the placebo (p = 0.009). Preeclamspia was severe in one aspirin and in six placebo recipients (p = 0.06).
Conclusion: Daily ingestion of 60 mg of aspirin beginning at 24 weeks' gestation significantly reduced the occurrence of preeclampsia. |
| doi_str_mv | 10.1016/0002-9378(93)90351-I |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75692558</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000293789390351I</els_id><sourcerecordid>75692558</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-52acd54daabef21018a18802631d5c12852b84e8572d8c4e45e9c16db779227f3</originalsourceid><addsrcrecordid>eNp9kEtLxDAQgIMo67r6DxR6ENFDNUmbJrkIsvhYWPCi55AmU4z0ZdJd8d-bumWPXmYY5pth5kPonOBbgklxhzGmqcy4uJbZjcQZI-nqAM0JljwtRCEO0XyPHKOTED7Hkko6QzORcyYZmyO87r5T2wVIdOidd20yfIDX_U8ydEnvYQvtMGYwtW764PQpOqp0HeBsygv0_vT4tnxJ16_Pq-XDOjWZKIaUUW0sy63WJVQ03is0EQLTIiOWGUIFo6XIQTBOrTA55AykIYUtOZeU8ipboKvd3t53XxsIg2pcMFDXuoVuExRnhaSMiQjmO9D4LgQPleq9a7T_UQSrUZQa31ajhRjUnyi1imMX0_5N2YDdD01mYv9y6utgdF153RoX9ljOeRH_idj9DoPoYuvAq2ActAas82AGZTv3_x2_F5GDBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75692558</pqid></control><display><type>article</type><title>Low-dose aspirin therapy to prevent preeclampsia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Hauth, John C. ; Goldenberg, Robert L. ; Parker, C. Richard ; Philips, Joseph B. ; Copper, Rachel L. ; DuBard, Mary B. ; Cutter, Gary R.</creator><creatorcontrib>Hauth, John C. ; Goldenberg, Robert L. ; Parker, C. Richard ; Philips, Joseph B. ; Copper, Rachel L. ; DuBard, Mary B. ; Cutter, Gary R.</creatorcontrib><description>Objective: Our aim was to test the hypothesis that acetylsalicylate (aspirin) treatment reduces the incidence or severity of pregnancy-associated hypertension.
Study Design: Patients were nulliparous, healthy, and with a singleton gestation at between 20 and 22 weeks' gestation. A sample size of 600 patients was calculated on the basis of p ≤ 0.05 and 90% power of observation. A 2-week placebo-controlled “run-in” was used to select compliant patients. Randomization occurred at 24 weeks, with 60 mg of aspirin or placebo treatment from randomization to delivery.
Results: Follow-up was maintained on 99% of the patients. The randomized patients had a 94% pill compliance index. At randomization, serum thromboxane medians were similar in both groups. Thromboxane B2 levels in the aspirin group decreased significantly from baseline at 29 to 31 weeks, 34 to 36 weeks, and at delivery as compared with an overall increase in the placebo group. Preeclampsia developed in five of 302 women (1.7%) who received aspirin versus 17 of 302 (5.6%) who received the placebo (p = 0.009). Preeclamspia was severe in one aspirin and in six placebo recipients (p = 0.06).
Conclusion: Daily ingestion of 60 mg of aspirin beginning at 24 weeks' gestation significantly reduced the occurrence of preeclampsia.</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/0002-9378(93)90351-I</identifier><identifier>PMID: 8475955</identifier><identifier>CODEN: AJOGAH</identifier><language>eng</language><publisher>Philadelphia, PA: Mosby, Inc</publisher><subject>Adult ; aspirin ; Aspirin - administration & dosage ; Biological and medical sciences ; Eclampsia - prevention & control ; Female ; Genital system. Reproduction ; Humans ; Hypertension - prevention & control ; Medical sciences ; Parity ; Pharmacology. Drug treatments ; Pre-Eclampsia - prevention & control ; Preeclampsia prevention ; Pregnancy ; Pregnancy Complications, Cardiovascular - prevention & control ; Pregnancy Outcome ; Prospective Studies ; serum thromboxane ; Thromboxane B2 - blood</subject><ispartof>American journal of obstetrics and gynecology, 1993-04, Vol.168 (4), p.1083-1093</ispartof><rights>1993 Mosby</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-52acd54daabef21018a18802631d5c12852b84e8572d8c4e45e9c16db779227f3</citedby><cites>FETCH-LOGICAL-c386t-52acd54daabef21018a18802631d5c12852b84e8572d8c4e45e9c16db779227f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9378(93)90351-I$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4776880$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8475955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hauth, John C.</creatorcontrib><creatorcontrib>Goldenberg, Robert L.</creatorcontrib><creatorcontrib>Parker, C. Richard</creatorcontrib><creatorcontrib>Philips, Joseph B.</creatorcontrib><creatorcontrib>Copper, Rachel L.</creatorcontrib><creatorcontrib>DuBard, Mary B.</creatorcontrib><creatorcontrib>Cutter, Gary R.</creatorcontrib><title>Low-dose aspirin therapy to prevent preeclampsia</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>Objective: Our aim was to test the hypothesis that acetylsalicylate (aspirin) treatment reduces the incidence or severity of pregnancy-associated hypertension.
Study Design: Patients were nulliparous, healthy, and with a singleton gestation at between 20 and 22 weeks' gestation. A sample size of 600 patients was calculated on the basis of p ≤ 0.05 and 90% power of observation. A 2-week placebo-controlled “run-in” was used to select compliant patients. Randomization occurred at 24 weeks, with 60 mg of aspirin or placebo treatment from randomization to delivery.
Results: Follow-up was maintained on 99% of the patients. The randomized patients had a 94% pill compliance index. At randomization, serum thromboxane medians were similar in both groups. Thromboxane B2 levels in the aspirin group decreased significantly from baseline at 29 to 31 weeks, 34 to 36 weeks, and at delivery as compared with an overall increase in the placebo group. Preeclampsia developed in five of 302 women (1.7%) who received aspirin versus 17 of 302 (5.6%) who received the placebo (p = 0.009). Preeclamspia was severe in one aspirin and in six placebo recipients (p = 0.06).
Conclusion: Daily ingestion of 60 mg of aspirin beginning at 24 weeks' gestation significantly reduced the occurrence of preeclampsia.</description><subject>Adult</subject><subject>aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Eclampsia - prevention & control</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Hypertension - prevention & control</subject><subject>Medical sciences</subject><subject>Parity</subject><subject>Pharmacology. Drug treatments</subject><subject>Pre-Eclampsia - prevention & control</subject><subject>Preeclampsia prevention</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Cardiovascular - prevention & control</subject><subject>Pregnancy Outcome</subject><subject>Prospective Studies</subject><subject>serum thromboxane</subject><subject>Thromboxane B2 - blood</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAQgIMo67r6DxR6ENFDNUmbJrkIsvhYWPCi55AmU4z0ZdJd8d-bumWPXmYY5pth5kPonOBbgklxhzGmqcy4uJbZjcQZI-nqAM0JljwtRCEO0XyPHKOTED7Hkko6QzORcyYZmyO87r5T2wVIdOidd20yfIDX_U8ydEnvYQvtMGYwtW764PQpOqp0HeBsygv0_vT4tnxJ16_Pq-XDOjWZKIaUUW0sy63WJVQ03is0EQLTIiOWGUIFo6XIQTBOrTA55AykIYUtOZeU8ipboKvd3t53XxsIg2pcMFDXuoVuExRnhaSMiQjmO9D4LgQPleq9a7T_UQSrUZQa31ajhRjUnyi1imMX0_5N2YDdD01mYv9y6utgdF153RoX9ljOeRH_idj9DoPoYuvAq2ActAas82AGZTv3_x2_F5GDBg</recordid><startdate>19930401</startdate><enddate>19930401</enddate><creator>Hauth, John C.</creator><creator>Goldenberg, Robert L.</creator><creator>Parker, C. Richard</creator><creator>Philips, Joseph B.</creator><creator>Copper, Rachel L.</creator><creator>DuBard, Mary B.</creator><creator>Cutter, Gary R.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930401</creationdate><title>Low-dose aspirin therapy to prevent preeclampsia</title><author>Hauth, John C. ; Goldenberg, Robert L. ; Parker, C. Richard ; Philips, Joseph B. ; Copper, Rachel L. ; DuBard, Mary B. ; Cutter, Gary R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-52acd54daabef21018a18802631d5c12852b84e8572d8c4e45e9c16db779227f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Eclampsia - prevention & control</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Hypertension - prevention & control</topic><topic>Medical sciences</topic><topic>Parity</topic><topic>Pharmacology. Drug treatments</topic><topic>Pre-Eclampsia - prevention & control</topic><topic>Preeclampsia prevention</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Cardiovascular - prevention & control</topic><topic>Pregnancy Outcome</topic><topic>Prospective Studies</topic><topic>serum thromboxane</topic><topic>Thromboxane B2 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hauth, John C.</creatorcontrib><creatorcontrib>Goldenberg, Robert L.</creatorcontrib><creatorcontrib>Parker, C. Richard</creatorcontrib><creatorcontrib>Philips, Joseph B.</creatorcontrib><creatorcontrib>Copper, Rachel L.</creatorcontrib><creatorcontrib>DuBard, Mary B.</creatorcontrib><creatorcontrib>Cutter, Gary R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hauth, John C.</au><au>Goldenberg, Robert L.</au><au>Parker, C. Richard</au><au>Philips, Joseph B.</au><au>Copper, Rachel L.</au><au>DuBard, Mary B.</au><au>Cutter, Gary R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose aspirin therapy to prevent preeclampsia</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>1993-04-01</date><risdate>1993</risdate><volume>168</volume><issue>4</issue><spage>1083</spage><epage>1093</epage><pages>1083-1093</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><coden>AJOGAH</coden><abstract>Objective: Our aim was to test the hypothesis that acetylsalicylate (aspirin) treatment reduces the incidence or severity of pregnancy-associated hypertension.
Study Design: Patients were nulliparous, healthy, and with a singleton gestation at between 20 and 22 weeks' gestation. A sample size of 600 patients was calculated on the basis of p ≤ 0.05 and 90% power of observation. A 2-week placebo-controlled “run-in” was used to select compliant patients. Randomization occurred at 24 weeks, with 60 mg of aspirin or placebo treatment from randomization to delivery.
Results: Follow-up was maintained on 99% of the patients. The randomized patients had a 94% pill compliance index. At randomization, serum thromboxane medians were similar in both groups. Thromboxane B2 levels in the aspirin group decreased significantly from baseline at 29 to 31 weeks, 34 to 36 weeks, and at delivery as compared with an overall increase in the placebo group. Preeclampsia developed in five of 302 women (1.7%) who received aspirin versus 17 of 302 (5.6%) who received the placebo (p = 0.009). Preeclamspia was severe in one aspirin and in six placebo recipients (p = 0.06).
Conclusion: Daily ingestion of 60 mg of aspirin beginning at 24 weeks' gestation significantly reduced the occurrence of preeclampsia.</abstract><cop>Philadelphia, PA</cop><pub>Mosby, Inc</pub><pmid>8475955</pmid><doi>10.1016/0002-9378(93)90351-I</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9378 |
| ispartof | American journal of obstetrics and gynecology, 1993-04, Vol.168 (4), p.1083-1093 |
| issn | 0002-9378 1097-6868 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75692558 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult aspirin Aspirin - administration & dosage Biological and medical sciences Eclampsia - prevention & control Female Genital system. Reproduction Humans Hypertension - prevention & control Medical sciences Parity Pharmacology. Drug treatments Pre-Eclampsia - prevention & control Preeclampsia prevention Pregnancy Pregnancy Complications, Cardiovascular - prevention & control Pregnancy Outcome Prospective Studies serum thromboxane Thromboxane B2 - blood |
| title | Low-dose aspirin therapy to prevent preeclampsia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A04%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20aspirin%20therapy%20to%20prevent%20preeclampsia&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Hauth,%20John%20C.&rft.date=1993-04-01&rft.volume=168&rft.issue=4&rft.spage=1083&rft.epage=1093&rft.pages=1083-1093&rft.issn=0002-9378&rft.eissn=1097-6868&rft.coden=AJOGAH&rft_id=info:doi/10.1016/0002-9378(93)90351-I&rft_dat=%3Cproquest_cross%3E75692558%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75692558&rft_id=info:pmid/8475955&rft_els_id=000293789390351I&rfr_iscdi=true |